JP2009531068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531068A5 JP2009531068A5 JP2009503126A JP2009503126A JP2009531068A5 JP 2009531068 A5 JP2009531068 A5 JP 2009531068A5 JP 2009503126 A JP2009503126 A JP 2009503126A JP 2009503126 A JP2009503126 A JP 2009503126A JP 2009531068 A5 JP2009531068 A5 JP 2009531068A5
- Authority
- JP
- Japan
- Prior art keywords
- ras
- protein
- amino acid
- wild
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016914 ras Proteins Human genes 0.000 claims 43
- 108010014186 ras Proteins Proteins 0.000 claims 43
- 150000007523 nucleic acids Chemical group 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 24
- 235000018102 proteins Nutrition 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 125000000539 amino acid group Chemical group 0.000 claims 19
- 235000001014 amino acid Nutrition 0.000 claims 17
- 229940024606 amino acid Drugs 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 101710113436 GTPase KRas Proteins 0.000 claims 13
- 102100039788 GTPase NRas Human genes 0.000 claims 13
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 9
- 239000004471 Glycine Substances 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 101150040459 RAS gene Proteins 0.000 claims 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 108700042226 ras Genes Proteins 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78656806P | 2006-03-27 | 2006-03-27 | |
| PCT/US2007/063711 WO2007133835A2 (en) | 2006-03-27 | 2007-03-09 | Ras mutation and compositions and mehods related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014198353A Division JP2015043773A (ja) | 2006-03-27 | 2014-09-29 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531068A JP2009531068A (ja) | 2009-09-03 |
| JP2009531068A5 true JP2009531068A5 (enExample) | 2010-04-22 |
Family
ID=38694572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503126A Pending JP2009531068A (ja) | 2006-03-27 | 2007-03-09 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
| JP2014198353A Pending JP2015043773A (ja) | 2006-03-27 | 2014-09-29 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014198353A Pending JP2015043773A (ja) | 2006-03-27 | 2014-09-29 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7745128B2 (enExample) |
| EP (1) | EP2004666B1 (enExample) |
| JP (2) | JP2009531068A (enExample) |
| KR (1) | KR20090008290A (enExample) |
| CN (1) | CN101448848B (enExample) |
| AU (1) | AU2007249639B2 (enExample) |
| BR (1) | BRPI0709340A2 (enExample) |
| CA (1) | CA2647102A1 (enExample) |
| MX (1) | MX2008012392A (enExample) |
| SG (1) | SG170763A1 (enExample) |
| TW (1) | TW200806789A (enExample) |
| WO (1) | WO2007133835A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| AU2003301021C1 (en) * | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| US20100034840A1 (en) * | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) * | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| BRPI0711011A2 (pt) | 2006-05-18 | 2011-08-23 | Molecular Profiling Inst Inc | método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença |
| JP5570819B2 (ja) | 2007-02-02 | 2014-08-13 | グローブイミューン，インコーポレイテッド | 酵母を含む組成物および酵母を増殖させる方法 |
| EP2134358A1 (en) * | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| JP5547964B2 (ja) | 2007-06-29 | 2014-07-16 | 株式会社ステリック再生医科学研究所 | 生理活性物質を定着および発現させる方法 |
| KR100957555B1 (ko) | 2007-12-28 | 2010-05-11 | 덕성여자대학교 산학협력단 | Ｒａｓ 융합 단백질 |
| US20110081362A1 (en) * | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| US20100075326A1 (en) * | 2008-09-12 | 2010-03-25 | Cornell University | Yeast surface two-hybrid system for quantitative detection of protein-protein interactions |
| KR101153845B1 (ko) | 2008-11-10 | 2012-07-09 | 단국대학교 산학협력단 | Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임 |
| EP3181705A1 (en) * | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
| KR101791702B1 (ko) | 2009-04-03 | 2017-10-30 | 다이서나 파마수이티컬, 인크. | 비대칭 이중가닥 ｒｎａ에 의한 ｋｒａｓ의 특이적 저해를 위한 방법 및 조성물 |
| EP2419126B1 (en) | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| US8940486B2 (en) * | 2010-01-12 | 2015-01-27 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting KRAS and PIK3CA mutations |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| JP2013523178A (ja) * | 2010-04-12 | 2013-06-17 | レスポンス ジェネティクス，インコーポレイティド | Ｋｒａｓプライマーおよびプローブ |
| KR20130113447A (ko) | 2010-09-24 | 2013-10-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화 |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| CA2827497C (en) | 2011-02-15 | 2014-12-02 | Leica Biosystems Newcastle Ltd. | Method for localized in situ detection of mrna |
| US9556473B2 (en) | 2011-02-15 | 2017-01-31 | Leica Biosystems Newcastle Ltd | Methods for identifying nucleic acid sequences |
| AU2012228937B2 (en) * | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
| CN103501812A (zh) * | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| CN102796811B (zh) * | 2011-05-26 | 2013-12-18 | 上海赛安生物医药科技有限公司 | 检测kras突变的试剂及方法 |
| BR112013032381B1 (pt) | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| RU2017143985A (ru) | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
| US20150184246A1 (en) * | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| US9260714B2 (en) * | 2011-12-02 | 2016-02-16 | Roche Molecular Systems, Inc. | Suppression of non-specific amplification with high-homology oligonucleotides |
| KR101153844B1 (ko) | 2012-04-17 | 2012-06-20 | 단국대학교 산학협력단 | Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임 |
| CA2874905A1 (en) * | 2012-05-31 | 2013-12-05 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
| EP2864792A1 (en) * | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| US11105802B2 (en) * | 2012-12-10 | 2021-08-31 | Seattle Children's Hospital | Cell-free biofragment compositions and related systems, devices, and methods |
| WO2014186047A1 (en) | 2013-03-19 | 2014-11-20 | Globeimmune, Inc. | Yeast-based immunotherapy for chordoma |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| CA2910584A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| WO2015059677A1 (en) | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| US9775892B2 (en) * | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| WO2015123532A1 (en) * | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| KR102409372B1 (ko) * | 2014-04-11 | 2022-06-16 | 글로브이뮨 | 효모 면역 요법 및 타입 i 인터페론 감도 |
| CA2946759A1 (en) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| US12415995B2 (en) | 2014-08-01 | 2025-09-16 | Northwestern University | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders |
| US10829752B2 (en) * | 2014-08-01 | 2020-11-10 | Northwestern University | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders |
| EP3180463B1 (en) * | 2014-08-15 | 2023-08-30 | Medimmune, LLC | Detecting residual host cell proteins in recombinant protein preparations |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| CN107922472A (zh) * | 2015-06-16 | 2018-04-17 | 塔格瓦克斯公司 | Ras蛋白的突变的片段 |
| WO2017023840A1 (en) | 2015-08-03 | 2017-02-09 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| US10612032B2 (en) | 2016-03-24 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inducible production-phase promoters for coordinated heterologous expression in yeast |
| MX2018014554A (es) | 2016-05-27 | 2019-09-09 | Orum Therapeutics Inc | Anticuerpo penetrante de citosol y uso del mismo. |
| CA3042726A1 (en) | 2016-11-16 | 2018-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for identifying and expressing gene clusters |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| CN110709094A (zh) * | 2017-02-03 | 2020-01-17 | 威斯康星州医药大学股份有限公司 | Kras肽疫苗组合物及其使用方法 |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US10988754B2 (en) * | 2017-07-04 | 2021-04-27 | Cure Vac AG | Nucleic acid molecules |
| CN108484731A (zh) * | 2018-04-02 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108250269A (zh) * | 2018-04-02 | 2018-07-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440648A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440646A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108484730A (zh) * | 2018-04-02 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440647A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| KR20190143826A (ko) | 2018-06-21 | 2019-12-31 | 오름테라퓨틱 주식회사 | 세포/조직 특이적 세포 침투 항체 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CA3170359A1 (en) | 2020-04-14 | 2021-10-21 | Nantcell, Inc. | Yeast lysate covid-19 vaccine |
| CA3187258A1 (en) * | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2377188A (en) * | 1941-08-07 | 1945-05-29 | Schering Corp | Stabilized filter preparations |
| US2376884A (en) * | 1941-08-07 | 1945-05-29 | Schering Corp | Hydroquinone composition |
| US3856934A (en) * | 1970-06-24 | 1974-12-24 | A Kligman | Skin depigmentation |
| US3755560A (en) * | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
| US4136166A (en) * | 1977-04-18 | 1979-01-23 | Helena Rubinstein, Inc. | Skin lightening composition |
| US4229427A (en) * | 1978-06-28 | 1980-10-21 | The Procter & Gamble Company | Radioactive scanning agents with hydroquinone stabilizer |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| JPS57145803A (en) * | 1981-03-05 | 1982-09-09 | Sunstar Inc | External decoloring agent for skin |
| US4421769A (en) * | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US4466955A (en) * | 1982-06-09 | 1984-08-21 | Germaine Monteil Cosmetiques Corporation | Skin bleaching stick containing hydroquinone |
| US4725550A (en) | 1984-01-19 | 1988-02-16 | Research Foundation Of State University Of New York | Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma |
| US4871838A (en) | 1985-07-23 | 1989-10-03 | The Board Of Rijks Universiteit Leiden | Probes and methods for detecting activated ras oncogenes |
| US5591582A (en) | 1985-07-23 | 1997-01-07 | The Board Of Rijks Universiteit Leiden | Methods for detecting activated RAS oncogenes |
| US4792443A (en) * | 1985-12-20 | 1988-12-20 | Warner-Lambert Company | Skin bleaching preparations |
| US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
| JPH0474515A (ja) * | 1990-07-13 | 1992-03-09 | Toray Ind Inc | 酸素吸収体 |
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| US5523077A (en) * | 1992-02-06 | 1996-06-04 | Yale University | Composition and method for whitening skin |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| WO1995003335A1 (en) * | 1993-07-26 | 1995-02-02 | K.O. Technology, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| GB9422814D0 (en) | 1994-11-11 | 1995-01-04 | Medinnova Sf | Chemical method |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US6497860B1 (en) * | 1996-11-04 | 2002-12-24 | Children's Hospital Medical Center | Skin lightening compositions |
| US6060297A (en) * | 1997-04-17 | 2000-05-09 | Incyte Pharmaceuticals, Inc. | Rho protein |
| US5945306A (en) * | 1997-12-16 | 1999-08-31 | Incyte Pharmaceuticals, Inc. | Ras protein |
| US6207450B1 (en) * | 1998-04-15 | 2001-03-27 | University Of Iowa Research Foundation | Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| US6017710A (en) * | 1998-05-13 | 2000-01-25 | Axys Pharmaceuticals, Inc. | RAQ genes and their uses |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| AU7686100A (en) * | 1999-10-15 | 2001-04-23 | Yaeta Endo | Template molecule having broad applicability and highly efficient function meansof cell-free synthesis of proteins by using the same |
| AUPQ495700A0 (en) * | 2000-01-05 | 2000-02-03 | Johnson & Johnson Research Pty. Limited | Method for concurrent amplification and real time detection of polymorphic nucleic acid sequences |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| ES2260078T3 (es) | 2000-04-06 | 2006-11-01 | Seer Pharmaceuticals, Llc. | Sistema de administracion microbiana. |
| JP2004508056A (ja) * | 2000-09-06 | 2004-03-18 | グラクソ グループ リミテッド | ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答 |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| US7189759B2 (en) * | 2001-05-23 | 2007-03-13 | Medicis Pharmaceutical Corporation | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| US6699464B1 (en) * | 2001-07-30 | 2004-03-02 | Stiefel Laboratories, Inc. | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
| GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
| US20040185016A1 (en) * | 2002-07-30 | 2004-09-23 | Popp Karl F | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
| GB0229139D0 (en) * | 2002-12-13 | 2003-01-15 | Glaxo Group Ltd | Gene polymorphisms |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| US20100034840A1 (en) | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| JP5570819B2 (ja) | 2007-02-02 | 2014-08-13 | グローブイミューン，インコーポレイテッド | 酵母を含む組成物および酵母を増殖させる方法 |
| EP2134358A1 (en) | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
-
2007
- 2007-03-09 CN CN2007800183814A patent/CN101448848B/zh not_active Expired - Fee Related
- 2007-03-09 US US11/684,290 patent/US7745128B2/en active Active
- 2007-03-09 KR KR1020087026290A patent/KR20090008290A/ko not_active Ceased
- 2007-03-09 WO PCT/US2007/063711 patent/WO2007133835A2/en not_active Ceased
- 2007-03-09 MX MX2008012392A patent/MX2008012392A/es active IP Right Grant
- 2007-03-09 CA CA002647102A patent/CA2647102A1/en not_active Abandoned
- 2007-03-09 SG SG201102095-5A patent/SG170763A1/en unknown
- 2007-03-09 AU AU2007249639A patent/AU2007249639B2/en not_active Ceased
- 2007-03-09 BR BRPI0709340-3A patent/BRPI0709340A2/pt not_active IP Right Cessation
- 2007-03-09 EP EP07797163.8A patent/EP2004666B1/en not_active Not-in-force
- 2007-03-09 JP JP2009503126A patent/JP2009531068A/ja active Pending
- 2007-03-09 TW TW096108338A patent/TW200806789A/zh unknown
-
2010
- 2010-05-06 US US12/775,267 patent/US8470313B2/en active Active
-
2013
- 2013-03-13 US US13/799,496 patent/US20130344097A1/en not_active Abandoned
-
2014
- 2014-09-29 JP JP2014198353A patent/JP2015043773A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531068A5 (enExample) | ||
| US12083174B2 (en) | Immunogenic compositions and uses thereof | |
| KR101653555B1 (ko) | 단백질의 분비 생산 방법 | |
| JP6136930B2 (ja) | タンパク質の分泌生産法 | |
| JP2006081548A5 (enExample) | ||
| JP2010273685A5 (enExample) | ||
| CA3109083A1 (en) | Compositions and methods for genome engineering with cas12a proteins | |
| JP4480893B2 (ja) | トランスフェクションした細胞中の組換えタンパク質発現増大のためのホットスポットを含む発現ベクター | |
| CN110494567B (zh) | 生产rna的方法 | |
| CN114207134A (zh) | 工程化的mRNA序列及其用途 | |
| CA2932212A1 (en) | New methods to produce active tert | |
| US20190314523A1 (en) | Tumor-targeting synthetic adenoviruses and uses thereof | |
| JP2022527705A (ja) | 融合タンパク質およびその使用 | |
| CA3151762A1 (en) | Eukaryotic semi-synthetic organisms | |
| JP5977346B2 (ja) | Ｂ型肝炎ウイルス表面抗原のエピトープおよびその使用 | |
| KR20180053398A (ko) | Fc-함유 단백질의 발현 | |
| US8426572B2 (en) | Artificial entropic bristle domain sequences and their use in recombinant protein production | |
| CA3195967A1 (en) | Vectorized anti-tnf-? antibodies for ocular indications | |
| ES2382207T3 (es) | Procedimiento para la producción de L-glutamina | |
| US20090137004A1 (en) | Artificial entropic bristle domain sequences and their use in recombinant protein production | |
| CN119954929B (zh) | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 | |
| KR102655024B1 (ko) | 표적 특이적인 외래 유전자의 도입 방법 | |
| Azimova et al. | Study of the Immunogenicity of Combination of Recombinant RBD (Omicron) and Nucleocapsid Proteins of SARS-CoV-2 Expressed in Pichia Pastoris | |
| EP4615490A2 (en) | Iga protease polypeptide agents | |
| JP2023087682A (ja) | 新規プロモーター |